Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp brought in $6.5B of revenue over the twelve months to June 30, 2026, up 14.6% from a year earlier. Net income was $1B, a net margin of 15.4%. Operating cash flow minus capital spending left $1.3B of free cash flow in fiscal 2025. At June 30, 2026 it held $2.9B in cash against $598.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Edwards Lifesciences Corp
- Net worth
- Edwards Lifesciences Corp has a market value (market cap) of $50.3B at the latest share price, and shareholders' equity of $10.6B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $6.1B (+11.5% year on year), with net income of $1.1B. Over the 12 months to June 30, 2026: revenue $6.5B, net income $1B.
- Cash flow
- In fiscal 2025 operations brought in $1.6B of cash; after $260.2M of capital spending, free cash flow was $1.3B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Edwards Lifesciences Corp's next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Edwards Lifesciences Corp does
Edwards Lifesciences designs and manufactures medical devices focused on structural heart disease and critical care monitoring. The company is best known for its transcatheter aortic valve replacement systems, surgical heart valves, and hemodynamic monitoring technologies sold to hospitals. Its shares trade on NYSE under the ticker EW.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.1B | $1.1B | $1.83 | $1.3B |
| 2024 | $5.4B | $4.2B | $6.97 | $289.9M |
| 2023 | $5B | $1.4B | $2.30 | $642.8M |
| 2022 | $4.5B | $1.5B | $2.44 | $973.6M |
| 2021 | $5.2B | $1.5B | $2.38 | $1.4B |
| 2020 | $4.4B | $823.4M | $1.30 | $647.3M |
Full financial statements: income, balance sheet and cash flow
Where EW ranks in Health care
Latest SEC filings
What Edwards Lifesciences Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 28, 2026
- August 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 14% to $1.7B versus the same quarter last year; diluted EPS $0.42 versus $0.56.
- July 23, 2026
- June 12, 2026
- June 12, 2026
- May 27, 2026
- May 8, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 17% to $1.6B versus the same quarter last year; diluted EPS $0.66 versus $0.61.
- May 4, 2026
What is EW worth? A DCF from its reported cash flow
Insider trades
What the people running Edwards Lifesciences Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.5M worth of shares in the last 90 days and bought none on the open market. 4% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 14, 2026 | Markowitz WayneCVP, JAPAC | Shares withheld for tax | 568 | $47.9K |
| September 13, 2026 | Dahl Andrew M.SVP, Corporate Controller | Shares withheld for tax | 253 | $21.3K |
| September 11, 2026 | Markowitz WayneCVP, JAPAC | Shares withheld for tax | 355 | $30.8K |
| September 11, 2026 | Lippis Daniel J.CVP, TAVR | Exercised options | 619 | $45K |
| September 11, 2026 | Lippis Daniel J.CVP, TAVR | Soldpre-planned (10b5-1) | 619 | $54.2K |
| September 11, 2026 | Chopra DaveenCVP, TMTT, Surgical & IHFM | Shares withheld for tax | 398 | $34.5K |
| August 31, 2026 | Dahl Andrew M.SVP, Corporate Controller | Sold | 544 | $49.5K |
| August 28, 2026 | Bruls AnnetteCVP, EMEACLA | Sold | 2,644 | $237.9K |
Who owns EW
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.54% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,330 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 58,789,433 | +6,198,500 |
| Vanguard Capital Management LLC | 37,615,952 | -111,840 |
| Vanguard Portfolio Management LLC | 26,411,402 | +4,384 |
| State Street Corp | 26,321,940 | +25,541 |
| Jpmorgan Chase & Co | 22,783,175 | +1,038,463 |
| Wellington Management Group Llp | 16,827,967 | -5,183,134 |
| Geode Capital Management, LLC | 15,437,251 | +2,303,474 |
| Bank of New York Mellon Corp | 14,084,483 | -2,653,065 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 13,002,965 | +191,063 |
| Ninety One UK Ltd | 12,337,502 | -58,641 |
| Aristotle Capital Management, LLC | 8,665,712 | new |
| Fmr LLC | 8,435,949 | -6,067,821 |
| Norges Bank | 8,373,783 | new |
| Alliancebernstein L.P. | 8,660,416 | +5,193,061 |
| Brown Advisory Inc | 7,365,987 | +336,475 |
| Bank of America Corp | 6,692,424 | +2,809,005 |
| Artisan Partners Limited Partnership | 6,625,703 | +1,424,559 |
| Morgan Stanley | 6,339,368 | -721,508 |
| Deutsche Bank AG\ | 5,710,284 | -344,739 |
| Arrowstreet Capital, Limited Partnership | 5,677,344 | +3,786,485 |
Insiders
17 insiders reported holding 686,946 shares in total, about $59.9M at the last price.
| Holder | Shares |
|---|---|
| Bobo Donald E JrCVP,Strategy/Corp Development | 121,40998,611 held indirectly |
| Zovighian Bernard JCEO, Director | 107,7618,916 held indirectly |
| Mistras TheodoraCVP, Chief Financial Officer | 99,920 |
| Valeriani Nicholas JDirector | 84,423 |
| Ullem Scott B.CVP, Chief Financial Officer | 46,740 |
| Chopra DaveenCVP, TMTT, Surgical & IHFM | 43,926 |
| Lippis Daniel J.CVP, TAVR | 40,034 |
| Stone Heisz LeslieDirector | 34,199 |
| Markowitz WayneCVP, JAPAC | 19,371 |
| Bruls AnnetteCVP, EMEACLA | 17,984 |
Questions about EW
What does Edwards Lifesciences Corp do?
Edwards Lifesciences designs and manufactures medical devices focused on structural heart disease and critical care monitoring. The company is best known for its transcatheter aortic valve replacement systems, surgical heart valves, and hemodynamic monitoring technologies sold to hospitals. Its shares trade on NYSE under the ticker EW.
What is Edwards Lifesciences Corp's net worth?
Edwards Lifesciences Corp has a market value (market cap) of $50.3B at the latest share price, and shareholders' equity of $10.6B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Edwards Lifesciences Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $1B on revenue of $6.5B, a net margin of 15.4%.
How much revenue does Edwards Lifesciences Corp make?
Over the twelve months to June 30, 2026 Edwards Lifesciences Corp reported revenue of $6.5B. That is 14.6% more than a year earlier.
When did Edwards Lifesciences Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 14, 2026.
When is Edwards Lifesciences Corp's next earnings report?
Edwards Lifesciences Corp's next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare EW with
Follow EW
Get an email when Edwards Lifesciences Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow EW: get an email when it filesWhere the numbers come from
Financial figures are the values Edwards Lifesciences Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.